Search for: [Abstract = "ter achieving partial remission after the first or second line of the treatment or \(3\) was commenced in recurrent disease after non\-successful immunotherapy or chemotherapy. Before implementation of the treatment in the patients of the NET subgroup, receptor scintigraphy was performed to confirm the somatostatin receptors expression in the tumour, as well as the computed tomography \(CT\) of the involved area. Both procedures were essential to the treatment implementation. In every patient the serum level of AlAT, creatinine and chromogranin A together with completed blood count was estimated. Glomerular filtration rate \(GFR\) was also estimated. In every patient in the non\-Hodgkin lymphoma \(NHL\) subgroup CT of the abdomen and chest, complete blood count and bone marrow trepanobiopsy were performed to qualify the patient to the therapy. The serum AlAT and creatinine were also assessed. The dose of the 90\-DOTA\-TATE in NET patients was calculated according to the body surface area \(BSA\). The maximum dose did not exceed 7,4 GBq\/m2 \(200 mCi\/m2\) of BSA. In all patients the implementation of the therapeutic dose divided into 4 \- 5 cycles were planed. 22 patients received planed treatment, 2 patients received the therapy divided into 3 cycles, the other 1 patient received 7 cycles. The most often instituted dose was 100 mCi per treatment cycle. The cycles were repeated every 4 to 9 wee"]

Number of results: 1